Where did you work before you joined Synpromics?
I have worked in a variety of technical and business roles in the biotech industry over the last 25 years. I was previously founding CEO of Anatara Therapeutics (a life sciences company I managed through private fund raising and IPO in Australia); CEO of Ark Therapeutics with responsibility for leading the company through a transition to a viral contract development and manufacturing service model and ultimately a sale of the business assets; an advisor to Syncona Partners and VP – CMC for NightstaRx, an ophthalmology focused gene therapy company formed by Syncona. Previously at Intercell, I was responsible for building Intercell’s manufacturing capabilities in Europe and the USA. As Site Head for vaccine manufacturing operations in the UK I was responsible for the European and US licensure, pre-approval inspection and commercial supply of Ixiaro®, a Japanese Encephalitis vaccine, followed as Chief Operating Officer of Intercell USA Inc. based in Maryland, USA. Before joining Intercell I was Director of Operations at BioReliance Europe.
Why did you decide to join Synpromics?
I was impressed by the science developed by Michael and the team, and could see how the technology could be used to solve some of the problems I had faced in the development of novel therapeutics, particularly in cell and gene therapy, and was keen to see the technology and its applications developed.
What is your role and what do you enjoy most about it?
I came on board to lead the company through a fund raising, to expand our market and to build operational infrastructure – to build the business and create value. It is always exciting to be working with a team of great scientists with a technology that adds real value and can make a significant difference, and to partner with companies working at the leading edge of novel technologies who are making a real difference in improving human health.